Invitae is a genetic testing company that aims to bring genetic information into mainstream medical practice by offering comprehensive genetic testing for less than $1,000 per indication. Invitae has grown rapidly since launching in 2013, increasing its test menu from 200 genes to over 1,000 genes while decreasing costs per sample and increasing test volume and revenue. Invitae plans to continue expanding its test menu, lowering costs, and pursuing reimbursement contracts to scale operations and make genetic information more accessible.
Advisor Live: Medicare Final Rules on OPPS and MPFSPremier Inc.
The Centers for Medicare & Medicaid Services (CMS) published the outpatient prospective payment system (OPPS) interim final rule and the Medicare physician fee schedule (PFS) final rule on November 1 and 2, 2016. The finalized changes will be effective December 31, 2016. Comments on the OPPS interim final rule are due January 1, 2017.
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
Advisor Live: Medicare Final Rules on OPPS and MPFSPremier Inc.
The Centers for Medicare & Medicaid Services (CMS) published the outpatient prospective payment system (OPPS) interim final rule and the Medicare physician fee schedule (PFS) final rule on November 1 and 2, 2016. The finalized changes will be effective December 31, 2016. Comments on the OPPS interim final rule are due January 1, 2017.
Exact Sciences chairman and CEO Kevin Conroy delivered the company's presentation at the 2015 Baird 2015 Healthcare Conference in New York at 9:40 a.m. ET on Wednesday, Sept. 9.
An archive of the webcast is available here: http://wsw.com/webcast/baird43/register.aspx?conf=baird43&page=exas&url=http://wsw.com/webcast/baird43/exas/index.aspx
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Genetic Technologies Limited is a diversified molecular diagnostics
company developing tools for the prediction and assessment of cancer
risk to help physicians proactively manage patient health. The
Company’s lead products, ‘GeneType for Breast Cancer’ and
‘GeneType for Colorectal Cancer’, are clinically validated risk
assessment tests that are first in their class. The Company’s
development pipeline includes new tests for COVID-19, Type 2
diabetes, cardiovascular disease, prostate cancer, and melanoma.
Listed on the ASX in 2000 and NASDAQ in 2005, Genetic
Technologies has been a leader in the development and
commercialization of genetic risk assessment technology for 20 years.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Genetic Technologies Limited is a diversified molecular diagnostics
company developing tools for the prediction and assessment of cancer
risk to help physicians proactively manage patient health. The
Company’s lead products, ‘GeneType for Breast Cancer’ and
‘GeneType for Colorectal Cancer’, are clinically validated risk
assessment tests that are first in their class. The Company’s
development pipeline includes new tests for COVID-19, Type 2
diabetes, cardiovascular disease, prostate cancer, and melanoma.
Listed on the ASX in 2000 and NASDAQ in 2005, Genetic
Technologies has been a leader in the development and
commercialization of genetic risk assessment technology for 20 years.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
With the October 1 liability shift looming in the U.S., there are many misconceptions surrounding EMV and what it means for consumers and merchants. Follow the conversation on Twitter: @Verifone #EMVchat
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Equity research presentation and investment pitch on the viability of Invitae Corporation as a potential company to include in our portfolio. Analyzed the business model, strategic outlook, and competitive positioning of Invitae Corporation within the pre-natal genetic diagnostic testing industry. Includes DCF valuation of Invitae Corporation. My partner and I rated Invitae Corporation as a strong buy.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.